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Abstract 
Background: Studies have demonstrated that whereas some opioids have little 
effect on immunity (e.g. buprenorphine), others can be immunosuppressive (e.g. 
morphine) or immunostimulatory (e.g. tramadol). However, a variety of approaches 
have been used and the findings are variable. We hypothesised that opioids have 
differential effects on immunity via direct actions on neutrophils, monocytes, NK and 
T cells and this is the first study to systematically evaluate the influence of eight 
opioids on neutrophil and monocyte phagocytosis and oxidative burst responses, 
natural killer (NK) cell cytotoxicity and T cell responsiveness in vitro.  
Methods: Peripheral blood was obtained from healthy volunteers and the effects of 
clinically relevant concentrations of morphine, tramadol, fentanyl, buprenorphine, 
methadone, oxycodone, diamorphine and codeine on phagocytosis and oxidative 
burst responses were determined using whole blood flow cytometry. The influence of 
opioids on the capacity of resting and IL-2 stimulated isolated peripheral blood 
mononuclear cells (PBMCs) to kill NK cell-sensitive K562 cells, and the 
responsiveness of PBMC sub-populations to IL-2 and polyclonal stimulation were 
also evaluated.  
Results: Methadone, oxycodone and diamorphine inhibited the production of IL-6 by 
IL-2 stimulated PBMCs. None of the opioids influenced the other measured immune 
parameters, although there was a trend for morphine, tramadol, fentanyl and 
buprenorphine to inhibit phagocytosis and oxidative burst responses to E.coli. 
Conclusions: Preliminary studies using standardised in vitro methodologies have 
demonstrated that some therapeutic opioids suppress IL-6 production. Although this 
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might potentially suppress bacterial defence mechanisms, it would have little direct 
effect on anti-cancer immunity. These findings should be confirmed in larger in vitro 
and clinical studies. 
 
Keywords: opioids; phagocytosis; oxidative burst; NK cell cytotoxicity; T cells; 
immunoregulation 
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1. Introduction  
 The commonly prescribed opioids in palliative care include morphine, tramadol, 
fentanyl, buprenorphine, methadone, oxycodone, diamorphine and codeine [1, 2] 
and these exhibit multisystem effects due to their interactions with receptors that are 
targeted by the endogenous opioid system. The reported presence of opioid 
receptors on activated T lymphocyte, monocyte, and granulocyte populations [3] 
suggests that opioids might also influence immune function.  
 As the immune system plays a key role in anti-tumour immunity and protection 
against infection, both of which are important in the non-terminal patient receiving 
palliative care, its impairment might have an influence on the clinical progress of 
patients that require pain relief. This concept appears to be clinically relevant, as 
opioids have been associated with an increased risk and severity of infection [4, 5]. 
Although previous in vitro and in vivo studies have demonstrated that opioids can 
have differential effects on the immune system, these have used different 
methodologies and the conclusions are variable. Notwithstanding this, the general 
consensus is that some opioids (eg, buprenorphine) seem to have no effects on 
immune function, whereas others tend to be immunosuppressive (eg, morphine) or 
immunostimulatory (eg, tramadol) [2, 6, 7]. This is likely due to a combination of 
direct effects on immune cells and, in vivo, via indirect effects that involve centrally-
mediated mechanisms and the systemic production and release of 
immunomodulatory mediators [8-10]. In vitro experiments indicate that the 
immunoregulatory effects of morphine are mediated via interactions with µ opioid 
receptors (MORs) on immune cells [3].  
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 Opioid-immune system interactions are complex and their differential 
immunological consequences depend on the molecular structure of the opioids, their 
receptor binding profiles and non-opioid mediated effects such as serotonin re-
uptake inhibition in the case of tramadol [11]. The discovery that morphine, fentanyl, 
buprenorphine, methadone and oxycodone are Toll-like receptor 4 (TLR4) agonists 
suggests that they might also directly influence innate immune responsiveness [12], 
probably via a MOR mediated mechanism [13]. It has also recently been 
demonstrated that chronic administration of morphine can abrogate the natural 
tolerance to the proinflammatory effects of lipopolysaccharide due to effects on TLR4 
[14]. 
 Opioids also have indirect effects on immune cells in vivo via centrally-produced 
mediators such as immunosuppressive glucocorticoids that are released by the 
hypothalamic-pituitary-adrenal (HPA) axis, or the release of immunosuppressive 
amines from the sympathetic nervous system (SNS) which innervates lymphoid 
organs [10].  
 The choice of opioids that are prescribed in clinical practice could therefore be 
critical in patients with cancer or infection, in whom impaired immunity could 
significantly influence their clinical course. Although therapeutic opioids 
predominantly exert their analgesic effects via the MOR pathway, their analgesic and 
side-effects differences are mediated through variations in drug-receptor 
interactions. We therefore hypothesised that opioids also have differential effects on 
immunity via direct actions on neutrophils, monocytes, NK and T cells. This study 
therefore used standardised and consistent methodologies to systematically assess 
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Ethical approval for this study was obtained from the University of Sheffield 
Medical School Research Ethics Committee (Reference Number: SMBRER102).  
 
2.2. Blood samples  
Peripheral blood from healthy volunteers aged 25-33 years old was collected into 
lithium heparin Vacutainers (BD Biosciences, Oxford, UK) following written informed 
consent. All blood samples were taken in the morning or early afternoon. At least 
three subjects were used to screen for the effects of each opioid on the immune 
function parameters and the number of experimental replicates was increased if 
effects were suggested. 
 
2.3. Opioids 
Morphine, tramadol, fentanyl, buprenorphine, methadone, oxycodone, 
diamorphine and codeine were obtained from the Pharmacy at the Royal 
Hallamshire Hospital, Sheffield, UK. Each opioid was diluted with RPMI 1640 
medium containing 10% v/v fetal bovine serum (FBS; Invitrogen Ltd., Paisley, UK), 
100 µg/ml streptomycin and 100 U/ml penicillin or phosphate buffered saline (PBS) 
immediately prior to each experiment. Concentrations of the opioids used in the 
7 | P a g e  
 
current study (Table 1) were reflective of in vivo levels that have been reported in 
volunteer and clinical studies [15-22]. 
Although diamorphine and codeine are prodrugs of morphine, and some other 
opioids have effects mediated by their metabolites, these opioids were included to 
produce a baseline of the direct immune effects of the (pro)drugs, including potential 
non-MOR effects. For example, tramadol was included because its analgesic effect 
depends on the active metabolite, the molecule may also exert immune effects via 
serotoninergic pathways [6, 23]. Furthermore, diamorphine has been shown to have 
direct effects on exon 11 variants of MOR-1 receptor [24]. 
 
 
Opioid Final concentrations used in this study (ng/ml) 
Morphine  20 100 500 2,500 
Tramadol  80 400 2,000 10,000 
Fentanyl  0.8 4 20 100 
Buprenorphine 0.8 4 20 100 
Methadone 20 100 500 2,500 
Oxycodone 4 20 100 500 
Diamorphine  10 50 250 1,250 
Codeine 16 80 400 2,000 
 
Table 1: Opioid concentrations used in this study. 
The opioid concentrations used in this study relate to those that are found clinically, with the maximal 
clinical concentration falling in the middle of the concentrations used, with 5x dilutions above and 
below the clinical maximum plasma concentration. In the NK cell cytotoxicity assay, the central two 
concentrations were used. In the phagocytosis and oxidative burst assay the lowest concentration 
was used in addition to these. In the T cell and cytokine assays all concentrations were used (with the 
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addition of a supra-maximal concentration, 10x that of the top concentration, for the T cell assays). 
 
2.4. Influence of opioids on neutrophil and monocyte function  
The influence of opioids on neutrophil and monocyte phagocytic and oxidative 
burst responses was determined by whole blood flow cytometry using 
PHAGOBURST® and BURSTTEST® kits (both ORPEGEN Pharma GmbH, 
Heidleberg, Germany) according to the supplier’s recommended protocols. For these 
assays, heparinized whole blood (50µl) was incubated for 60 min at 37°C with 50µl 
of opioid or PBS. For the evaluation of phagocytosis, samples were then incubated 
with 10µl FITC-labelled opsonised E.coli ( bacteria/ml) for 10 min at 37°C (4°C as a 
control). Opioids were not washed out. Following quenching (to exclude fluorescent 
signals from adhered rather than internalized bacteria), erythrocytes were lysed, 
samples washed and the proportion of neutrophils and monocytes that had 
phagocytosed FITC-E.coli and the total amount of E.coli that had been 
phagocytosed (on the basis of the median fluorescent intensity, MFI) were analysed 
using a BD Biosciences FACSCalibur™ flow cytometer and BD Biosciences 
CELLQuest™ acquisition and analysis software. For the oxidative burst reaction, 
opioid-treated samples and controls were incubated for 10 min at 37°C with 10µl 
opsonised, unconjugated E.coli ( bacteria/ml), 8.1µM phorbol myristate acetate 
(PMA), 5µM N-formyl-methionine-leucine-phenylalanine (fMLP) or washing solution 
(negative control). Dihydrorhodamine 123 substrate solution (10µl) was then added, 
and the samples were incubated at 37°C for a further 10 min. Opioids were not 
washed out. Erythrocytes were lysed, samples washed and the proportion of cells 
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undergoing the oxidative burst reaction and the intensity of this response were 
analysed. For both assays, data on a minimum of 5,000 events (cells) in the 
monocyte region and more than 10,000 cells in the neutrophil region were collected. 
The reproducibility of these assays (coefficient of variation) is 0.1% for the proportion 
of neutrophils undergoing the oxidative burst reaction to E. coli; 4.8% for the MFI of 
this response; 1.1% for the proportion of monocytes undergoing the oxidative burst 
reaction to E. coli; and 6.5% for the MFI of this response (ORPEGEN Pharma 
GmbH). 
 
2.5. Isolation of peripheral blood mononuclear cells (PBMCs) 
Peripheral blood mononuclear cells (PBMCs) were used for the natural killer 
(NK) cell and T cell assays. PBMCs were separated from whole blood by density 
gradient centrifugation (300xg for 30 minutes at room temperature, no brake) using 
Nycoprep 1.077 (Axis-Shield POCAS, Oslo, Norway). As platelet-derived secretory 
products can inhibit NK cell cytotoxicity responses, platelets were removed by 
layering 10 ml of Nycoprep 1.068 (comprising 4 parts Nycoprep 1.077 and 1 part 
PBS) under 10 ml of the PBMC interface acquired during the first centrifugation and 
samples were centrifuged at 400xg for 15 min at room temperature (no brake) [25]. 
The supernatant was removed and the cell pellet was washed and re-suspended in 
supplemented RPMI 1640 medium, as detailed above ( viable cells/ml).  
 
2.6. Influence of opioids on natural killer (NK) activation and function  
The effect of opioids on the capacity of PBMCs to kill NK cell-sensitive K562 
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human erythroleukemic target cells (Health Protection Agency Culture Collection, 
Porton Down, UK) was determined using flow cytometry, as described previously 
[25]. Briefly, PBMCs ( cells/well) were stimulated with 100 U/ml (50 ng/ml) 
recombinant human IL-2 (Miltenyi Biotec) in the presence or absence of different 
opioid concentrations for 3 days (37°C, 5% v/v , 100% humidity) in 96-well microtiter 
plates. PBMCs were harvested, washed (to remove IL-2 and opioids) and incubated 
with MitoTracker™ Green (MTG; Invitrogen Ltd., Paisley, UK) labelled K562 target 
cells (effector:target (E:T) ratios of 100:1, 50:1, 25:1 and 12.5:1) in 12x75 mm 
polycarbonate tubes for 3 h at 37°C. The viability stain propidium iodide (PI; Sigma-
Aldrich, Gillingham, UK) was added to the samples 10 min prior to analysis and the 
proportions of viable (MTG+PI-) and non-viable (MTG+PI+) K562 target cells were 
determined using a BD LSRII flow cytometer (BD Biosciences) [25]. 
For each E:T cell ratio, NK cell cytotoxicity was represented by the proportion of 
non-viable K562 cells (number of MTG+PI+ K562 cells/total number of MTG+ labelled 
K562 cellsx100) following corrections being made for background target cell death. 
The area under the cytotoxic curve (AUCC), a composite calculation of cytotoxicity 
which incorporates all four E:T ratios [26], was also determined as we have 
previously shown that this increases the reproducibility of the assay [25]. 
 
2.7. Influence of opioids on the activation of peripheral blood mononuclear cells  
The influence of opioids on the ability of PBMC sub-populations to be activated 
by IL-2 (100 U/ml) and anti-CD3/anti-CD28 monoclonal antibody (mAb) coated 
beads (  Suppression Inspector, 1:1 bead:cell ratio, Miltenyi Biotec Ltd, Bisley, UK) 
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was determined by flow cytometry. For this, PBMCs were incubated with opioids or 
PBS and anti-CD3/anti-CD28 mAb coated beads for 3 days at 37°C, 5% v/v  and 
100% humidity. Cells were harvested and the supernatants stored at -80°C for 
subsequent analysis of IL-1β, IL-6, IL-8, IL-10, IL-17A, IFN-γ and TNF-α levels using 
Cytometric Bead Arrays (CBAs) and a BD FACSArray™ (both BD Biosciences). 
The expression of the activation markers CD25 and CD69 by CD4+ and CD8+ T 
cell subpopulations and NK cells following stimulation in the presence and absence 
of opioids were determined using a BD™ LSRII flow cytometer and BD Biosciences 
FACSDiva™ software. For the flow cytometric analysis, PBMCs (1.) were incubated 
with 0.5µl mouse serum for 15 min at room temperature, after which they were 
incubated with Pacific Blue™-conjugated anti-CD4 (clone RPA-T4, BioLegend),  
Alexa Fluor™ 700-conjugated anti-CD8a (clone RPA-T8, BioLegend), FITC-
conjugated anti-CD16/CD56 (clones LNK16, MEM-188, AbD Serotec), PE-
conjugated anti-CD25 (clone MEM-181, AbD Serotec) and anti-CD69 (clone FN50, 
BioLegend) mAbs for 30 min at 4°C. Cells were washed and kept on ice prior to flow 
cytometry. The viability stain 7-Aminoactinomycin D (1µl/100µl cell suspension, 
Cambridge Biosciences, Cambridge, UK) was added 5-10 min before analysis. 
For the analysis, cells were initially identified on the basis of their size and 
granularity. Doublets and dead cells were excluded and the proportion of CD4+ T 
cells, CD8+ T cells and NK cells expressing CD25 and CD69, and the intensity of 
expression were determined. Unstained and cells incubated with non-reactive 
isotype-matched reagents served as controls. 
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2.8. Statistical analysis 
Data were analysed in Microsoft Excel 2010 and Predictive Analytics SoftWare 
(PASW) version 18.0 using a paired 2-tailed Student t-test (*P value < 0.05) and are 
presented as mean ± standard error of the mean (SEM), or as individual 
experiments, as indicated.  
 
1. 3. RESULTS 
3.1 Effect of opioids on neutrophil and monocyte phagocytosis and oxidative burst 
responses 
None of the opioids inhibited phagocytosis, although there was a non-significant 
trend for morphine, tramadol, fentanyl and buprenorphine to inhibit the intensity of 
the phagocytic response (Figure 1).  
None of the opioids had any effect on the proportion of neutrophils that 
underwent the oxidative burst responses by fMLP, PMA and E. coli, although there 
was a non-significant trend for responses to E. coli to be inhibited and PMA to be 
enhanced, by morphine, tramadol, fentanyl and buprenorphine (Figure 2). These 
data suggest that the capacity of opioids to influence the recruitment of cells into 
oxidative burst and its intensity is dependent on the inducing stimuli. The effects of 
opioids were cell type-dependent, as the ‘effects profile’ for monocytes differed from 
that which was observed for neutrophils (Figure 3). It is therefore possible that these 
opioids have differential effects on various aspects of immunity.  
 
3.2. Effect of opioids on CD16+CD56+ natural killer (NK) cells 
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The incubation of PBMCs for 3 days with IL-2 (100 U/ml) enhanced the ability of 
NK cells to kill K562 target cells and this was unaffected by any of the opioids tested 
(Figure 4). IL-2 increased CD69, but not CD25 expression on NK cells and neither of 
these markers were influenced by any of the opioids (data not shown). Incubation of 
PBMCs with anti-CD3/anti-CD28 mAb coated beads for 3 days also increased the 
proportion of NK cells that expressed CD69 and, to a greater extent, the intensity of 
CD69, but not CD25 expression (data not shown). The expression of CD69 and 
CD25 was not affected by any of the opioids (data not shown). 
 
3.3. Effect of opioids on T cell activation and cytokine secretion 
Opioids had no consistent effect on the activation status (CD25, CD69 
expression) of CD4+ and CD8+ T cells following a 3-day incubation of PBMCs with 
anti-CD3/anti-CD28 mAb coated beads. This remained the case if opioids were 
added at the same time, 1 day after or 1 day before the anti-CD3/anti-CD28 mAb 
coated beads, or if platelets were present in the PBMC preparations (data not 
shown, representative graph - Figure 5). Anti-CD3/anti-CD28 mAb coated beads had 
little effect on cytokine secretion and none of the opioids tested had an influence on 
this (data not shown). 
The stimulation of PBMCs with IL-2 increased the production of IL-1β, IL-6, IL-8, 
IL-17A, IL-10, IFN-γ and TNF-α. The only consistent statistically significant effect 
was that methadone, oxycodone and diamorphine decreased IL-6 production from 
IL-2 stimulated PBMCs (Figure 6).   
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2. 4. Discussion and Conclusions 
Opioids exert actions on most biological systems and have differing 
physicochemical properties which can elicit a range of pharmacodynamic effects. 
This is the first systematic analysis of the in vitro effects of eight commonly used 
therapeutic opioids at clinically relevant concentrations across a standardised profile 
of tests that reflect innate and adaptive immune potential. 
 
4.1. Neutrophil and monocyte phagocytosis  
Previous studies using various methodologies have evaluated some therapeutic 
opioids in vitro and in vivo and have yielded a range of effects on phagocytosis. 
Morphine has generally inhibited phagocytosis [27-32], whereas tramadol [31], 
fentanyl [33] and methadone [32, 34] generally had no effect on phagocytosis. 
Although none of the opioids in the current study had any statistically significant 
effects, there was a trend for morphine, tramadol, fentanyl and buprenorphine to 
inhibit neutrophil and monocyte phagocytosis.  
 
4.2. Neutrophil and monocyte oxidative burst reaction 
Previous in vitro and in vivo studies have generally shown morphine [30, 32] and 
methadone [30, 34] to inhibit oxidative burst, whereas fentanyl has been reported to 
have no effect on neutrophil oxidative burst responses in healthy volunteers [16]. 
Although no opioid tested had a consistent effect on oxidative burst responses in the 
current study, there was a trend for morphine, tramadol, fentanyl, buprenorphine and 
methadone to inhibit oxidative burst responses.  
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4.3. Natural killer cell cytotoxicity 
The previous literature using differing methodologies is often conflicting, however 
in general morphine [35], fentanyl [7, 36], methadone [37] and diamorphine [38] 
decrease NK cell cytotoxicity, whereas buprenorphine has no effect [36] and 
tramadol enhances it [6, 39]. In the current study, none of the opioids had any effect 
on the activation status or cytotoxicity of unstimulated and stimulated human NK 
cells in PBMC preparations. This suggests that the reported in vivo manifestations of 
opioids on NK cells are mediated indirectly through central pathways.  
 
4.4. Effect of opioids on IL-2 and anti-CD3/anti-CD28 mAb-induced T cell activation 
and cytokine secretion 
This is the first in vitro study to have assessed the effect of opioids on the 
activation status of human T cells on the basis of CD25 and CD69 expression. Anti-
CD3/anti-CD28 mAb stimulation activated CD4+ and CD8+ T cells, which was not 
affected by any of the opioids. Previous in vitro studies, using proliferation or cytolytic 
assays, are generally consistent with the current study, in that clinically relevant 
concentrations of morphine, methadone and diamorphine had no effect [40-42].  
Cytokine secretion from PBMCs was used as another measure of lymphocyte 
activation. There are several heterogeneous studies relating to the effects of opioids 
on cytokine secretion in the literature. In general, morphine has been reported to 
decrease IL-1β, IL-2, IL-4, IL-6, IL-12 and IFN-γ production [9, 27, 43], but to have 
mixed effects on IL-10 and TNF levels [9, 43]. Fentanyl has been demonstrated to 
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decrease IL-2 and IFN-γ production, whereas buprenorphine has been reported to 
have no effect [36]. Codeine has been shown to increase IL-8 and TNF-α production 
[8]. In post-operative studies, morphine has been reported to inhibit IL-2 production, 
which was unaffected by fentanyl and either unaffected or increased by tramadol [44, 
45]. 
The only significant effect which was been observed in the current study was 
that methadone, oxycodone and diamorphine significantly decreased IL-6 secretion 
from IL-2 stimulated PBMCs. IL-6 has a range of pro- and anti-inflammatory effects 
and its levels correlate with the acute phase reactant C-Reactive Protein [46]. IL-6 
also influences lipid and bone metabolism [47]. Any inhibition of IL-6 production 
could therefore have multiple downstream effects on several organ systems. 
The findings of this systematic evaluation indicate that further studies are 
needed with larger numbers of subjects to evaluate the effects of morphine, 
tramadol, fentanyl, buprenorphine and methadone on neutrophil and monocyte 
phagocytosis and oxidative burst. As NK and T cells are likely to be modified by 
indirect effects of opioids, these also need further evaluation in in vivo models. 
However, all of these aspects of immune defence need to be investigated in human 
clinical models with disease outcomes as endpoints in order to better inform clinical 
practice.   
 
4.6. Limitations of present study 
The use of in vitro models meant that only the direct effects of the opioids were 
measured on immune cells. However, clinically used opioids also have indirect 
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effects via the SNS and HPA axis, which may modulate or negate these direct 
effects in whole animals. The sample size was small, as the primary aim of this study 
was to screen for immune effects of many opioids and a larger sample may have 
shown greater differences between opioids. Thus caution is needed as to not over-
interpret the results. However, retrospective power and sample size calculations 
have been performed for those assays for which opioids potentially showed an effect 
and some of these calculations have a power greater than 80% with a sample size 
compatible with that performed. Only healthy volunteers were included and although 
the immune cells were activated in vitro this might not truly reflect effects that could 
be present on cells from different patient groups, especially those with immune 
activation or suppression from other biological or therapeutic causes. Further 
confirmatory studies should therefore employ larger samples, using the same opioids 
in all subjects and using a test-retest method to look for variations within individuals 
as well as between subjects. 
 
4.7. Conclusion 
Opioids are currently prescribed for pain on the basis of their reported efficacy, 
their clinically recognisable toxicities and economic factors. The findings of this 
small, but systematic healthy volunteer preliminary investigation indicate that opioids 
might differentially influence IL-6 production by a direct effect on the cells, with 
methadone, oxycodone and diamorphine being suppressive. There might also be 
direct effects of morphine, tramadol, fentanyl, buprenorphine and methadone on 
neutrophil and monocyte phagocytosis and oxidative burst, which warrant further 
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investigation with more subjects. However, further investigation in human clinical 
models with disease outcomes as endpoints is paramount.   
Despite the potential negative impact of certain opioids on aspects of immune 
function in vitro, optimal pain control remains the key clinical goal, as pain itself might 
be immunosuppressive [6, 48]. In keeping with the move towards personalised 
medicine, including for pain management [49], with more comprehensive clinical 
data, we could more rationally select the opioid to administer to an individual patient 
with cancer, in order to optimise pain control without potentially negatively impacting 
on their immune function. However, with currently available data, opioid choice 
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Figure 1 Effect of morphine, tramadol, fentanyl, buprenorphine and oxycodone 
on neutrophil and monocyte phagocytosis. The proportion of neutrophils and 
monocytes phagocytosing FITC-E.coli (left panel) and the intensity of the phagocytic 
response (median channel of fluorescent intensity, MFI; right panel). Data are 
means ± SEM from 5 subjects (n=4 for monocytes at 20 and 100 ng/ml of morphine) 
and are presented as absolute differences from the no opioid control. No opioid 
(baseline) values (mean ± SEM) are included at the top of the graphs. No statistically 
significant differences between the responsiveness of opioid-treated and untreated 
cells were detected (paired Student t-test) 
 
Figure 2 Effect of morphine, tramadol, fentanyl, buprenorphine and oxycodone 
on neutrophil oxidative burst responses. The proportion of neutrophils 
undergoing the oxidative burst reaction (left panel) and the intensity of this response 
in these positive cells, median channel of fluorescent intensity (MFI, right panel), to 
fMLP, PMA and E.coli. Data are means ± SEM from 5 subjects and are presented as 
absolute differences from the no opioid control. No opioid control (baseline) values 
(mean ± SEM) are included at the top of the graphs. Statistically significant 
differences between the responsiveness of opioid-treated and untreated cells is 
indicated (* = P<0.05, paired Student t-test) 
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Figure 3 Effect of morphine, tramadol, fentanyl, buprenorphine and oxycodone 
on monocyte oxidative burst responses. The proportion of monocytes undergoing 
the oxidative burst reaction (left panel) and the intensity of this response in these 
positive cells, median channel of fluorescent intensity (MFI, right panel), to fMLP, 
PMA and E.coli. Data are means ± SEM from 5 subjects and are presented as 
absolute differences from the no opioid control. No opioid control (baseline) values 
(mean ± SEM) are included at the top of the graphs. Statistically significant 
differences between the responsiveness of opioid-treated and untreated cells is 
indicated (* = P<0.05, paired Student t-test) 
 
Figure 4 Representative figure illustrating the effect of morphine on IL-2 
induced NK cell cytotoxicity of K562 target cells. Isolated PBMCs, without 
platelets, were incubated for 3 days with IL-2 and opioid. Controls comprised 
unstimulated and IL-2 stimulated cells cultured in the absence of opioid. The 
adjusted area under the cytotoxic curve (AUCC) was calculated using the formula 
presented in the methods. Values for the adjusted AUCC for each of the 
experimental conditions are indicated in the legend. No statistical difference in the 
NK cell cytotoxicity of untreated and morphine-treated PBMCs was observed (paired 
Student t-test). Data are means ± SEM of 3 subjects 
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Figure 5 Representative figure illustrating the effect of morphine on CD69 
expression by CD4+ and CD8+ T cells. The proportion (%) of CD4+ and CD8+ cells 
expressing CD69 (upper panel) and the intensity of CD69 expression on positive 
cells (median channel of fluorescent intensity, MFI; lower panel). PBMCs were 
incubated with the indicated concentrations of morphine for 3 days prior to assessing 
CD69 expression. All cells, other than the unstimulated control, were activated with 
anti-CD3/anti-CD28 mAb coated beads for 3 days, added at the same time as the 
opioid. No statistical difference between the responsiveness of opioid-treated and 
untreated anti-CD3/anti-CD28 mAb stimulated cells was observed (paired Student t-
test). Data are means ± SEM from 5 subjects  
 
Figure 6 Effect of morphine, methadone, oxycodone and diamorphine on IL-6 
secretion by IL-2 stimulated cells. Effect of methadone, oxycodone and 
diamorphine on IL-6 production by IL-2 (left Y-axis, blue) and Miltenyi anti-CD3/anti-
CD28 mAb coated bead (right Y-axis, red) stimulated PBMCs. IL-6 concentrations 
are presented on the Y-axes, in pg/ml. Unstimulated (unstim) and stimulated (stim) 
controls without opioid are included. IL-6 levels in IL-2 stimulated PBMCs were 
decreased by methadone at all concentrations, 4, 20 and 500 ng/ml of 
oxycodone, and 10, 50 and 1250 ng/ml of diamorphine decreased  levels 
(P<0.05; paired Student t-test). Data are means ± SEM from a minimum of 3 
subjects 
 
 
